Rankings / Longevity — Supplements
Censavudine / TPN-101 (LINE-1 suppression)
Longevity · Reverse transcriptase inhibitor (NRTTI)
Tier D+
Bottom line
Read Off Label grades Censavudine / TPN-101 (LINE-1 suppression) as D+ (3.7/10) based on preclinical for aging evidence, med benefit magnitude, and a med-risk safety profile.
Transposon Therapeutics.
Studied, labeled, or reported-use context: Oral; doses from prior neurology trials — Investigational; not individualized guidance.
What the evidence says
Transposon Therapeutics. ARPA-H PROSPR award (up to $22M) funds a ~200-participant 48-week trial in healthy adults aged 60-65 testing whether suppressing LINE-1 retrotransposons improves mobility, cognition and vitality (the Gorbunova/Sedivy inflammaging hypothesis). Existing safety from PSP/ALS-FTD Phase 2 trials de-risks the repurposing; no aging-specific human readout yet. Frontier. Grant/industry-sponsored.
Mechanism
Nucleoside reverse-transcriptase translocation inhibitor (originally an HIV drug) repurposed to suppress LINE-1 retrotransposon activity; reactivated transposable elements are an emerging driver of inflammaging and genomic instability.
Studied, labeled, or reported dose & route
Oral; doses from prior neurology trials
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Censavudine / TPN-101 (LINE-1 suppression)'s effects?
- Read Off Label rates the evidence for Censavudine / TPN-101 (LINE-1 suppression) as Preclinical for aging and the benefit magnitude as med, producing an overall grade of D+ (3.7/10). Transposon Therapeutics.
- What safety findings are reported for Censavudine / TPN-101 (LINE-1 suppression)?
- Censavudine / TPN-101 (LINE-1 suppression) has a med risk profile in the database. Med (clinical safety established in neuro trials; aging use unproven) Legal status: Investigational (repurposing; ARPA-H PROSPR-funded).
- What doses or routes are reported for Censavudine / TPN-101 (LINE-1 suppression)?
- Oral; doses from prior neurology trials This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Censavudine / TPN-101 (LINE-1 suppression) work?
- Nucleoside reverse-transcriptase translocation inhibitor (originally an HIV drug) repurposed to suppress LINE-1 retrotransposon activity; reactivated transposable elements are an emerging driver of inflammaging and genomic instability.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.